Nathan Dowden Sells 11,894 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) COO Nathan Dowden sold 11,894 shares of the business’s stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $13.05, for a total transaction of $155,216.70. Following the transaction, the chief operating officer owned 198,588 shares in the company, valued at approximately $2,591,573.40. The trade was a 5.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Entrada Therapeutics Price Performance

NASDAQ TRDA traded up $0.30 on Wednesday, hitting $13.50. 210,880 shares of the stock were exchanged, compared to its average volume of 236,376. The company has a market capitalization of $516.78 million, a PE ratio of -3.90 and a beta of -0.12. The business’s fifty day moving average is $11.16 and its 200 day moving average is $8.83. Entrada Therapeutics, Inc. has a 52 week low of $4.93 and a 52 week high of $13.66.

Entrada Therapeutics (NASDAQ:TRDA) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.94) earnings per share for the quarter, topping the consensus estimate of ($1.32) by $0.38. The company had revenue of $1.30 million for the quarter, compared to analyst estimates of $7.41 million. Entrada Therapeutics had a negative net margin of 565.48% and a negative return on equity of 39.83%. Analysts predict that Entrada Therapeutics, Inc. will post 1.12 EPS for the current fiscal year.

Institutional Investors Weigh In On Entrada Therapeutics

A number of institutional investors have recently made changes to their positions in TRDA. Royce & Associates LP grew its position in shares of Entrada Therapeutics by 54.8% in the third quarter. Royce & Associates LP now owns 345,507 shares of the company’s stock valued at $2,004,000 after purchasing an additional 122,256 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Entrada Therapeutics during the 2nd quarter worth approximately $166,000. Los Angeles Capital Management LLC boosted its stake in Entrada Therapeutics by 60.6% in the 2nd quarter. Los Angeles Capital Management LLC now owns 44,632 shares of the company’s stock valued at $300,000 after purchasing an additional 16,840 shares during the period. GSA Capital Partners LLP bought a new stake in Entrada Therapeutics in the 3rd quarter valued at $325,000. Finally, Allspring Global Investments Holdings LLC grew its holdings in Entrada Therapeutics by 9.8% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 17,495 shares of the company’s stock valued at $176,000 after buying an additional 1,560 shares in the last quarter. Institutional investors own 86.39% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on TRDA shares. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Entrada Therapeutics in a research report on Monday, December 29th. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Entrada Therapeutics in a research note on Wednesday, February 18th. Guggenheim raised Entrada Therapeutics to a “strong-buy” rating in a report on Wednesday, February 11th. Oppenheimer began coverage on shares of Entrada Therapeutics in a research report on Wednesday, January 28th. They set an “outperform” rating and a $21.00 price objective for the company. Finally, Wall Street Zen upgraded shares of Entrada Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $18.50.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.